WHOOP nearly tripled its valuation overnight. On March 31, the company closed a $575 million Series G at a $10.1 billion valuation — up from roughly $3.6 billion. Abbott Laboratories and Mayo Clinic are now investors. And somewhere in there, a few million subscribers are still paying $240 to $360 a year to see their recovery scores every morning.

I’m one of those subscribers. Been wearing WHOOP since the 4.0, currently on a 5.0 with the standard tier. My first reaction to the fundraise wasn’t excitement. It was: where is all this money going, and will any of it improve the thing I’m actually paying for?

Quick Verdict

Factor	What It Means for Subscribers
$10.1B valuation	High growth expectations; WHOOP needs to grow revenue fast
Abbott investment	Medical-grade sensor tech is coming to the band
Mayo Clinic investment	Clinical validation, possible insurance/wellness integrations
$1.1B bookings run rate	Subscription model is working. You’re the product that works
Feature trajectory	More health features, likely at higher tiers or prices
Current subscription value	Unchanged today, but the pressure to monetize harder is real

If you’re a current subscriber: Nothing changes tomorrow. But the next 12 months will tell you whether WHOOP is building a better recovery tracker or pivoting to a medical device company that happens to have a fitness app.

If you’re considering WHOOP: Wait three to six months. See what the Abbott partnership actually produces before committing to $240/year.

What $575 Million Actually Buys

Let’s be specific about the investors, because they’re not the usual venture capital names.

Abbott Laboratories makes FreeStyle Libre continuous glucose monitors. They make cardiac rhythm management devices. They make blood testing equipment used in hospitals worldwide. Abbott doesn’t invest in fitness wearables for fun. They invest because they see a path to medical-grade consumer health monitoring. That’s a different business than telling you your recovery score is 64% and you should take it easy today.

Mayo Clinic is one of the largest and most respected medical research institutions on the planet. Their involvement signals clinical ambitions: FDA-cleared health alerts, validated screening tools, maybe integration with electronic health records down the road.

Combined with WHOOP’s existing ECG and blood pressure features in the MG tier, the trajectory is clear. WHOOP wants to be a medical device. Not a fitness gadget. Not a recovery tracker for CrossFit athletes. A platform that detects AFib, screens for sleep apnea, and maybe (eventually) connects to your doctor’s systems.

That’s an interesting company. It’s also not the company most subscribers signed up for.

The $1.1 Billion Number You Should Care About

WHOOP reported a $1.1 billion bookings run rate in 2025. That’s up 103% year-over-year. For context, “bookings” means committed subscription revenue — not one-time hardware sales. This is recurring money from people like you and me paying monthly or annually.

Here’s why that number matters more than the valuation.

WHOOP doesn’t sell hardware. The band comes with the subscription. Every dollar of revenue comes from subscribers. When WHOOP tripled its valuation to $10.1 billion, it did so on the back of subscriber growth and retention. You are not just the customer. You are the asset. Your subscription is what the investors are buying.

That creates a specific tension. A $10 billion company backed by medical investors needs to grow revenue. There are only a few ways to do that:

1. Get more subscribers. WHOOP has been expanding internationally and moving into women’s health, hormonal tracking, and blood panel partnerships. Smart. Lots of runway.
2. Charge existing subscribers more. WHOOP already has three tiers ($199/yr, $240/yr, $360/yr for MG). Expect new tiers. Expect features to migrate from lower tiers to higher ones. Expect price increases.
3. Monetize the health data. With Abbott and Mayo Clinic at the table, anonymized health datasets become incredibly valuable for research and pharmaceutical development. WHOOP’s privacy policy will be worth watching closely.
4. Sell to employers and insurers. Corporate wellness programs. Insurance premium discounts for wearing a WHOOP. This is where the real scale money lives, and Abbott’s distribution network makes it possible.

I’m not speculating wildly here. These are the standard playbook moves for a health-tech company at this stage. Some of them benefit subscribers. Some of them benefit investors at your expense.

What Might Actually Get Better

I’ll give WHOOP credit — not everything about this fundraise is a warning sign. Some of the money will go toward things subscribers want.

Better sensors. Abbott’s biosensor expertise could meaningfully improve WHOOP’s hardware. Current WHOOP sensors are good but not medical-grade. An Abbott partnership could bridge that gap, giving you clinical-quality heart rate, SpO2, and maybe even glucose monitoring without a separate CGM patch. That’s a real upgrade.

Clinical validation. Right now, WHOOP’s recovery score is a proprietary algorithm. It correlates with how you feel (usually), but it’s not clinically validated in the way a medical device would be. Mayo Clinic’s involvement could produce published research backing WHOOP’s metrics with actual peer-reviewed data. That would make the data more useful, not just for biohackers but for coaches, physical therapists, and physicians.

Strength training improvements. The Passive MSK update was a step in the right direction. More sensor data and better algorithms (funded by half a billion dollars of new capital) could finally make WHOOP Strain scores accurate for lifters. Longtime pain point. Maybe it finally gets fixed.

FDA clearances. WHOOP MG already does ECG and blood pressure insights. With Abbott and Mayo Clinic backing, expect more FDA-cleared features. Atrial fibrillation detection, sleep apnea screening, maybe blood oxygen alerts that actually trigger clinical follow-up instead of just showing you a number.

What Might Get Worse (or More Expensive)

Here’s where I get nervous.

Tier creep. WHOOP went from one price to three tiers in under two years. The MG tier launched at $360/year with ECG and blood pressure. New Abbott-powered features will almost certainly land in a fourth tier — or the MG price goes up. Features you currently have at $240/year might eventually require a higher plan. That’s how tiered pricing works once the tier count starts climbing.

Subscription fatigue compounding. I wrote about the fitness subscription pile-up two weeks ago. WHOOP at $240, Strava at $80, Garmin Connect+ at $70 — the annual cost of tracking your fitness keeps growing. A WHOOP that adds medical features at premium pricing only accelerates the problem.

Identity shift. WHOOP built its brand on elite athletic performance. Recovery scores. Strain optimization. The sleep coach. That’s the product most subscribers love. A medical-grade pivot means the product roadmap tilts toward health monitoring features that matter for a 55-year-old at cardiac risk, not a 30-year-old training for a marathon. Both are valid users. But the product can’t fully serve both without getting bloated or splitting into two apps.

Data monetization pressure. A $10 billion valuation means investors expect returns. Subscriber revenue alone might not be enough. The temptation to monetize health data — anonymized or otherwise — is significant when you have millions of users generating continuous biometric streams. WHOOP has been decent on privacy so far. But “so far” is doing a lot of work in that sentence.

How WHOOP’s Valuation Compares

Some context on what $10.1 billion means in this space.

Company	Valuation / Market Cap	Primary Revenue
WHOOP	$10.1B (private)	Subscriptions (~$240-360/yr)
Oura	~$5.2B (last round)	Hardware + subscription ($70/yr)
Garmin	~$42B (public)	Hardware + Connect+ ($70/yr)
Peloton	~$2B (public)	Hardware + subscriptions ($44/mo)
Fitbit (Google)	Acquired for $2.1B	Hardware + Fitbit Premium ($80/yr)

WHOOP is now valued at roughly twice Oura, five times Peloton, and nearly five times what Google paid for Fitbit. On subscription revenue alone. No hardware margins. That’s either a testament to the subscription model’s power or a sign that the valuation has outrun the actual product.

For comparison, Oura charges $70/year for its subscription (with hardware sold separately). Ultrahuman charges nothing. WHOOP’s $240/year minimum is already the most expensive subscription in wearables. At a $10 billion valuation, the pressure to justify that number with revenue growth makes price stability unlikely.

What I’m Telling People Who Ask

Three scenarios. Pick yours.

You’re a current WHOOP subscriber who uses it daily. Keep it. The product works. Recovery scores are useful. Sleep tracking is among the best available. The fundraise doesn’t change what’s on your wrist today. But pay monthly if your plan allows it. Don’t lock into an annual right before a company with $575 million in fresh capital starts rearranging its pricing structure.

You’re a current subscriber who checks the app twice a week. Reassess. At $240/year, you’re paying $4.60 per week for data you’re barely looking at. A no-subscription alternative might give you 80% of the insight at zero ongoing cost. Or an Oura Ring at $70/year for the subscription after a one-time hardware purchase. WHOOP’s value proposition requires daily engagement. If you’re not engaging daily, you’re subsidizing the medical pivot for people who are.

You’re thinking about starting WHOOP. Wait. Seriously. The product roadmap is about to change. New Abbott-powered features could launch in the next six to twelve months. Pricing tiers will almost certainly shift. If you start now at $240/year and WHOOP launches a better tier at $300 in October, you’ll either pay more or feel stuck on an inferior plan. Let the fundraise play out. Let the first Abbott-partnership features ship. Then decide.

The Bigger Question Nobody’s Asking

Should a recovery tracker be worth $10 billion?

I wear WHOOP every day. I check my recovery score every morning. I adjust my training based on it. But if I’m honest — really honest — I could get 80% of that value from an Apple Watch and a free HRV app. Or from Oura at a fraction of the ongoing cost. WHOOP’s edge has always been the specificity of its recovery algorithm and the obsessive focus on strain and sleep. That edge is real, but it’s narrowing. Every competitor is adding recovery scores. Garmin’s Body Battery is surprisingly good. Oura’s Readiness score is comparable. Apple is inching closer.

A $10 billion valuation says WHOOP isn’t competing with Oura and Garmin anymore. It’s competing with Abbott’s own glucose monitors and medical-grade wearables. That’s a different market with different expectations, different regulatory requirements, and different users.

For subscribers who just want to know if today is a rest day or a hard training day? That mission hasn’t changed. But the company carrying it out just got a lot bigger, a lot more complex, and a lot more beholden to investors who care about healthcare revenue, not your PR on a half marathon.

Keep wearing the band. Keep using the data. But watch what happens next, because the WHOOP you subscribed to and the WHOOP that’s worth $10 billion might not end up being the same product.

---

Analysis based on WHOOP’s Series G announcement from March 31, 2026. I’ve been a WHOOP subscriber since the 4.0 generation, currently on WHOOP 5.0 standard tier at $240/year. Pricing reflects US rates as of April 2026. Investor details sourced from public reporting by Bloomberg and TechCrunch.